Thymogen (Glu-Trp) is a dipeptide derived from thymus tissue — one of the simplest and most extensively studied thymus-derived immunoregulatory peptides in the Khavinson bioregulator series. As a two-amino acid thymic peptide, Thymogen directly stimulates T-lymphocyte maturation and activation, enhances natural killer (NK) cell cytotoxicity, and modulates cytokine production — functioning as a concentrated signal of thymic activity that the immune system is designed to recognize and respond to.

The thymus produces multiple peptide hormones that regulate the immune system beyond its role in T-cell education. These thymic hormones — thymosin-α1, thymulin, thymopoietin, and thymic humoral factor — all signal to peripheral immune cells to maintain activation thresholds, proliferative capacity, and functional balance. Thymogen, derived from the thymus tissue peptide pool, carries this class of thymic signals in its simplest dipeptide form. Its small size (two amino acids) gives it pharmacological advantages: high stability, excellent bioavailability across mucosal surfaces, and the ability to reach immune cells throughout the body rapidly following intranasal or sublingual administration.

The immunological mechanism of Thymogen centers on T-cell biology. Thymogen treatment increases the proportion of mature CD3+, CD4+, and CD8+ T cells in peripheral blood, enhances T-cell proliferative responses to mitogenic stimulation, increases IL-2 production (the primary T-cell growth and activation cytokine), and augments NK cell cytotoxicity against tumor cell targets. These effects collectively strengthen cell-mediated immunity — the arm of adaptive immunity responsible for eliminating intracellular pathogens (viral infections), cancerous cells, and coordinating adaptive immune responses.

Khavinson group research has documented Thymogen's effects in multiple clinical contexts. In immunosuppressed patients (post-chemotherapy, elderly with documented immunosenescence), Thymogen courses normalized lymphocyte counts and improved T-cell functional parameters. In aging populations, Thymogen reduced the incidence and severity of respiratory infections over follow-up periods. In oncology adjunct applications, Thymogen was studied as an immune support agent during chemotherapy — maintaining immune function and potentially improving outcomes in studies of immune surveillance.

Thymogen is particularly well-suited for rapid immune support needs — its dipeptide simplicity allows effective intranasal administration with direct mucosal immune access, and its effects on T-cell activation are measurable within the first treatment course. This makes it appropriate for: pre-travel immune preparation, post-illness immune recovery, winter infection prevention protocols, and as an adjunct to the deeper structural thymic restoration provided by Crystagen and Thymosin Alpha-1.

Protocol: 1mg/day for 10 consecutive days, intranasally or sublingually, 2–4 times per year. The simplest and most accessible thymic peptide — complements Crystagen (epigenetic thymic restoration) and Thymosin Alpha-1 (direct TA-1 thymic hormone) in a complete thymic immune stack.